Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
出版年份 2019 全文链接
标题
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-02-04
DOI
10.1038/s41375-019-0379-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
- (2018) William L. Heaton et al. LEUKEMIA
- Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
- (2018) Dilana Staudt et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium
- (2017) Martin Griesshammer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients
- (2017) W.E. O'Gorman et al. JOURNAL OF AUTOIMMUNITY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Does ruxolitinib prolong the survival of patients with myelofibrosis?
- (2016) Francisco Cervantes et al. BLOOD
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- Monoclonal antibody 1.6.1 against human MPL receptor allows HSC enrichment of CB and BM CD34+CD38− populations
- (2016) Laurence Petit Cocault et al. EXPERIMENTAL HEMATOLOGY
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
- (2016) D A C Fisher et al. LEUKEMIA
- Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
- (2016) S. Elf et al. Cancer Discovery
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation
- (2016) S. Yang et al. Cancer Immunology Research
- The Role of Toll-Like Receptors in Hematopoietic Malignancies
- (2016) Darlene A. Monlish et al. Frontiers in Immunology
- IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
- (2015) C. Schinke et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Clinical and molecular genetic characterization of myelofibrosis
- (2015) Gabriela S. Hobbs et al. CURRENT OPINION IN HEMATOLOGY
- Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia
- (2015) J Khalife et al. LEUKEMIA
- Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm
- (2015) Eli R Zunder et al. Nature Protocols
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- Prognostication in MF: From CBC to cytogenetics to molecular markers
- (2014) Amy Zhou et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis
- (2014) R. Norfo et al. BLOOD
- Preclinical efficacy of MEK inhibition in Nras-mutant AML
- (2014) M. R. Burgess et al. BLOOD
- Physiological functions of TNF family receptor/ligand interactions in hematopoiesis and transplantation
- (2014) K. Mizrahi et al. BLOOD
- Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity
- (2014) Yuki Kagoya et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth
- (2014) Thanh U. Barbie et al. JOURNAL OF CLINICAL INVESTIGATION
- Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML
- (2014) Andrew Volk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
- (2014) Z. Zhu et al. Cancer Discovery
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Toll-like receptor alterations in myelodysplastic syndrome
- (2013) Y Wei et al. LEUKEMIA
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
- (2013) El-ad David Amir et al. NATURE BIOTECHNOLOGY
- MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice
- (2013) Jimmy L Zhao et al. eLife
- Discovery of Potent and Selective Covalent Inhibitors of JNK
- (2012) Tinghu Zhang et al. CHEMISTRY & BIOLOGY
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets
- (2011) K. L. Wong et al. BLOOD
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors
- (2011) Cornelis J.H. Pronk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE
- (2011) Peng Qiu et al. NATURE BIOTECHNOLOGY
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
- (2011) S. C. Bendall et al. SCIENCE
- The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor
- (2011) John P. Duffy et al. ACS Medicinal Chemistry Letters
- Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
- (2010) S. T. Oh et al. BLOOD
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
- (2010) R. T. Swords et al. BLOOD
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling
- (2010) Edwin Chen et al. CANCER CELL
- Highly multiparametric analysis by mass cytometry
- (2010) Olga Ornatsky et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
- (2009) A Pardanani et al. LEUKEMIA
- Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
- (2008) Jennifer Grosjean-Raillard et al. APOPTOSIS
- ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
- (2008) J Grosjean-Raillard et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now